Pharmaceutical company Akorn has received FDA approval for its generic version of the painkiller Dilaudid-HP.
The drug maker will begin shipping the treatment next month.
Akorn also said it had commenced work on an injectable version of vancomycin HCL, an antibiotic used to fight life-threatening infections.
Raj Raj, the firm’s interim chief executive officer, said: “These opportunities represent important milestones for our company and are integral to the execution of our strategy to deliver high value pharmaceuticals.”
Akorn specialises in hospital and ophthalmic pharmaceuticals. It also produces injectables, TB drugs, antidotes, analgesics and anaesthetics and rheumatoid arthritis treatments.
Copyright Press Association 2010